With a gain of over 7%, Inventiva was one of the biggest risers on the Paris market on Monday, after announcing the publication in the scientific journal Nature Communications of additional results from its Phase 2 clinical trial in NASH.

In a press release, the biopharmaceutical company points out that the phase 2b trial demonstrated an improvement in cardiometabolic health markers in patients treated with its small molecule lanifibranor.

According to Inventiva, improvements were observed in insulin resistance, lipid metabolism, glycemic control, systemic inflammation, hepatic steatosis and diastolic blood pressure.

Furthermore, the majority of patients with prediabetes at baseline treated with lanifibranor had normal fasting glucose levels at the end of treatment, i.e. after 24 weeks.

Finally, none of the lanifibranor-treated patients with normal glucose levels at baseline progressed to pre-diabetes during treatment, unlike the placebo group.

For Inventiva, these results demonstrate the potential of lanifibranor as a therapy that can address the entire biology of NASH, from insulin resistance to fibrosis.

Patients with non-alcoholic steatohepatitis (NASH) - a disease also known as steatohepatitis associated with metabolic dysfunction (MASH) - often present a cardiometabolic profile associated with cardiovascular disease.

Last month, analysts at Canadian broker Canaccord Genuity raised their price target on the stock, stating that they expected the product to be launched on the US market by 2027.

Copyright (c) 2024 CercleFinance.com. All rights reserved.